The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

New England Journal of Medicine

Volumn 341, Issue 8, 1999, Pages 556-562

  Alter, Miriam J ^a,d   Kruszon Moran, Deanna ^b   Nainan, Omana V ^a   McQuillan, Geraldine M ^b   Gao, Fengxiang ^a   Moyer, Linda A ^a   Kaslow, Richard A ^c   Margolis, Harold S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; DRUG ABUSE; FEMALE; GENE AMPLIFICATION; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; POVERTY; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; SEXUAL BEHAVIOR; UNITED STATES;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PREVALENCE; RISK FACTORS; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; SOCIOECONOMIC FACTORS; UNITED STATES; VIREMIA;

EID: 0033584440     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908193410802     Document Type: Article

References (41)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-4.
3. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
4. Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995;15:15-32.
5. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital and health statistics. Series 1. No. 32. Washington, D.C.: Government Printing Office, July 1994. (DHHS publication no. (PHS) 94-1308.)
6. Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods 1996;61:127-34.
7. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
8. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res 1983;12:387-95.
9. McQuillan GM, Coleman PJ, Kurszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-8.
10. Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias A. Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol 1985;22:641-4.
11. Coleman RM, Pereira L, Bailey PD, Dondero D, Wickliffe C, Nahmias A. Determination of herpes simplex virus type-specific antibodies by enzyme-linked immunosorbent assay. J Clin Microbiol 1983;18:287-91.
12. Mosley JW, Goodwin RF. Stability of serum-glutamic pyruvic transaminase activity on storage. Tech Bull Regist Med Technol 1965;35:183-7.
13. Mohadjer L, Montaquila J, Waksberg J, et al. National Health and Nutrition Examination Survey III: weighting and examination methodology. Hyattsville, Md.: National Center for Health Statistics, February 1996.
14. Ezzati T, Khare M. Nonresponse adjustments in a national health survey. In: 1992 Proceedings of the Section on Survey Research Methods. Alexandria, Va.: American Statistical Association, 1993:339-44.
15. Shah BV, Barnwell BG, Hurt PN, La Vange LM. SUDAAN users manual, release 5.30. Research Triangle Park, N.C.: Research Triangle Institute, 1991.
16. Kahn HA, Sempos CT. Statistical methods in epidemiology. New York: Oxford University Press, 1989.
17. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327: 1906-11.
18. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
19. Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-9.
20. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327:1899-905.
21. Lau JY, Mizokami M, Kolberg JA, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:281-9.
22. Mast EE, Alter MJ. Hepatitis C. Semin Pediatr Infect Dis 1997;8:17-22.
23. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 1997; 16:711-9.
24. Alter MJ, Gerety RJ, Smallwood LA, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93.
25. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
26. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:Suppl 1: 62S-65S.
27. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994;169:990-5.
28. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending Baltimore sexually transmitted diseases clinics - an analysis of 309 sex partnerships. J Infect Dis 1995; 171:768-75.
29. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-5.
30. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47(RR-19):1-39.
31. Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972;77:691-9.
32. Seeff LB, Wright EC, Zimmerman HJ, McCollum RW. VA cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. Am J Med Sci 1975;270: 355-62.
33. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994;34:464-70.
34. Francis DP, Hadler SC, Prendergast TJ, et al. Occurrence of hepatitis A, B, and non-A/non-B in the United States: CDC Sentinel County Hepatitis Study I. Am J Med 1984;76:69-74.
35. Lanphear BP, Linnemann CC Jr, Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745-50.
36. Thomas DL, Factor SH, Kelen GD, Washington AS, Taylor E Jr, Quinn TC. Viral hepatitis in health care personnel at the Johns Hopkins Hospital: the seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection. Arch Intern Med 1993;153:1705-12.
37. Panlilio AL, Shapiro CN, Schable CA, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. J Am Coll Surg 1995;180:16-24.
38. Shapiro CN, Tokars JI, Chamberland ME, American Academy of Orthopaedic Surgeons Serosurvey Study Committee. Use of hepatitis-B vaccine and infection with hepatitis B and C among orthopaedic surgeons. J Bone Joint Surg Am 1996;78:1791-800.
39. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
40. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
41. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26:25-105.